WESTMINSTER, Colo., Nov. 17 /PRNewswire-FirstCall/ -- Allos Therapeutics,
Inc. (Nasdaq: ALTH) today announced the election of Timothy P. Lynch to its
Board of Directors effective November 14, 2005. Mr. Lynch's appointment,
which expands the Board of Directors to eight members, further strengthens the
Board in the areas of financial and operational expertise. Mr. Lynch was also
appointed to serve as a member of the Audit Committee of the Board.
Mr. Lynch has significant experience as a public company executive within
the biotechnology industry and as an investment banker. He currently serves
as a consultant to several early-stage companies in the life science area.
After beginning his career as an investment banker at Chase Manhattan Bank
N.A. and Goldman, Sachs & Co, Mr. Lynch joined Elan Corporation PLC as
Director, Strategic Planning, where he managed corporate finance and mergers
and acquisitions matters. Mr. Lynch served as Chief Financial Officer of
Intermune, Inc. from 1999 to 2002, and as Chief Financial Officer of Tercica,
Inc. from 2002 through June 2005. During this time, Mr. Lynch was
instrumental in leading both Intermune and Tercica through their respective
IPOs, and negotiating multiple product license agreements. Mr. Lynch holds a
BA in Economics from Colgate University and an MBA from Harvard Business
School.
"We are delighted that Tim has joined the Allos Board of Directors," said
Michael E. Hart, President and Chief Executive Officer of Allos. "Tim's
financial and operational experience in biotech companies at similar stages of
growth to Allos will be a significant asset to our future plans for growth."
"I'm excited to be part of the Allos team," said Mr. Lynch. "I look
forward to contributing to Allos and it's future."
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company
focused on developing and commercializing innovative small molecule
therapeutics for the treatment of cancer. Our lead product candidate,
EFAPROXYN(TM) (efaproxiral), is a synthetic small molecule designed to
sensitize hypoxic, or oxygen-deprived, tumor tissue during radiation therapy.
EFAPROXYN is currently being evaluated as an adjunct to whole brain radiation
therapy in a pivotal Phase 3 trial in women with brain metastases originating
from breast cancer. Our other product candidates are: PDX (pralatrexate), a
small molecule chemotherapeutic agent (DHFR inhibitor) currently under
investigation as both a single agent and in combination therapy regimens in
patients with non-small cell lung cancer and Non-Hodgkin's lymphoma; and RH1,
a small molecule chemotherapeutic agent bioactivated by the enzyme
DT-diaphorase currently under evaluation in patients with advanced solid
tumors. For more information, please visit the Company's web site at:
http://www.allos.com.
SOURCE Allos Therapeutics
 back to top
Related links:
http://www.allos.com
CONTACT:
Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, +1-720-540-5227,
jneiman@allos.com
|
